Symptomatic bone marrow involvement in breast cancer - Clinical presentation, treatment, and prognosis: A single institution review of 22 cases

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 4025-4030

  Kopp, Hans Georg ^a   Krauss, Katja ^a   Fehm, Tanja ^a   Staebler, Annette ^b   Zahm, Jennifer ^a   Vogel, Wichard ^a   Kanz, Lothar ^a   Mayer, Frank ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bone marrow carcinomatosis; Breast cancer; Metastasis

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; GENTAMICIN; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD SMEAR; BONE MARROW DISEASE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE SEVERITY; ERYTHROBLASTOSIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 83055174792     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ardavanis A, Kountourakis P, Orphanos G and Rigatos G: Low-dose capecitabine in breast cancer patients with symptomatic bone marrow infiltration: a case study. Anticancer Res 25: 539-541, 2008. (Pubitemid 351362867)
2. Bjelic-Radisic V, Stoger H, Winter R, Beham-Schmid C and Petru E: Long-term control of bone marrow carcinosis and severe thrombocytopenia with standard-dose chemotherapy in a breast cancer patient: a case report. Anticancer Res 26: 1627-1630, 2006.
3. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G and Schlimok G: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342: 525-533, 2000. (Pubitemid 30117892)
4. Delsol G, Guiu-Godfrin B, Guiu M, Pris J, Corberand J and Fabre J: Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significance. Cancer 44: 1009-1013, 1979. (Pubitemid 10242235)
5. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmuller G and Klein CA: Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68, 2008. (Pubitemid 350309740)
6. Kamby C, Guldhammer B, Vejborg I, Rossing N, Dirksen H, Daugaard S and Mouridsen HT: The presence of tumor cells in bone marrow at the time of first recurrence of breast cancer. Cancer 60: 1306-1312, 1987. (Pubitemid 17152911)
7. Kamby C, Rasmussen BB and Kristensen B: Prognostic indicators of metastatic bone disease in human breast cancer. Cancer 68: 2045-2050, 1991.
8. O'Keane JC, Wolf BC and Neiman RS: The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 63: 1539-1543, 1989. (Pubitemid 19093277)
9. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
10. Rubins JM: The role of myelofibrosis in malignant leukoerythroblastosis. Cancer 51: 308-311, 1983.
11. Shamdas GJ, Ahmann FR, Matzner MB and Ritchie JM: Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 71: 3594-3600, 1993. (Pubitemid 23152670)
12. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA and Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res 68: 3108-3114, 2008.
13. Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H and Tang P: Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol 39: 1809-1815, 2008.
14. Winer EP: Optimizing endocrine therapy for breast cancer. J Clin Oncol 23: 1609-1610, 2005.
15. Yablonski-Peretz T, Sulkes A, Polliack A, Weshler Z, Okon E and Catane R: Secondary myelofibrosis with metastatic breast cancer simulating agnogenic myeloid metaplasia: report of a case and review of the literature. Med Pediatr Oncol 13: 92-96, 1985. (Pubitemid 15113163)